SIRT1 undergoes alternative splicing in a novel auto-regulatory loop with p53

PLoS ONE

Volumn 5, Issue 10, 2010, Pages

  Lynch, Cian J ^a,b   Shah, Zahid H ^a   Allison, Simon J ^a   Ahmed, Shafiq U ^a   Ford, Jack ^a   Warnock, Lorna J ^a   Li, Han ^a   Serrano, Manuel ^b   Milner, Jo ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ISOENZYME; PROTEIN P53; SIRTUIN 1; SIRT1 PROTEIN, HUMAN; SIRT1 PROTEIN, MOUSE;

AGING; ALTERNATIVE RNA SPLICING; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOREGULATION; CELL STRESS; CONTROLLED STUDY; ENZYME ACTIVITY; EXON; GENETIC CONSERVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAMMAL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; RNA STABILITY; ACETYLATION; ANIMAL; GENETICS; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MAMMALIA;

ACETYLATION; ALTERNATIVE SPLICING; ANIMALS; EXONS; HUMANS; MICE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIRTUIN 1; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78149421022     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013502     Document Type: Article

References (84)

1. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL, et al. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430: 686-689.
2. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, et al. (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450: 712-716.
3. Yamamoto H, Schoonjans K, Auwerx J (2007) Sirtuin functions in health and disease. Mol Endocrinol 21: 1745-1755.
4. Lavu S, Boss O, Elliott PJ, Lambert PD (2008) Sirtuins -novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov 7: 841-853.
5. Ghosh HS (2008) The anti-aging, metabolism potential of SIRT1. Curr Opin Investig Drugs 9: 1095-1102.
6. McBurney MW, Yang X, Jardine K, Hixon M, Boekelheide K, et al. (2003) The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol Cell Biol 23: 38-54.
7. Asher G, Gatfield D, Stratmann M, Reinke H, Dibner C, et al. (2008) SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell 134: 317-328.
8. Wang RH, Sengupta K, Li C, Kim HS, Cao L, et al. (2008) Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14: 312-323.
9. Nakahata Y, Sahar S, Astarita G, Kaluzova M, Sassone-Corsi P (2009) Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 324: 654-657.
10. Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, et al. (2009) Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science 324: 651-654.
11. Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH (2008) Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci USA 105: 9793-9798.
12. Banks AS, Kon N, Knight C, Matsumoto M, Gutie ́rrez-Jua ́rez R, et al. (2008) SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab 8: 333-341
13. Vogelstein B, Lane D, Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310.
14. Harris SL, Levine AJ (2005) The p53 pathway: positive and negative feedback loops. Oncogene 24: 2899-2908.
15. Soussi T, Lozano G (2005) p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 331: 834-842.
16. Gottlieb E, Haffner R, King A, Asher G, Gruss P, et al. (1997) Transgenic mouse model for studying the transcriptional activity of the p53 protein: age-and tissue-dependent changes in radiation-induced activation during embryo-genesis. EMBO J 16: 1381-1390.
17. Komarova EA, Chernov MV, Franks R, Wang K, Armin G, et al. (1997) Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. EMBO J 16: 1391-1400.
18. Choi J, Donehower LA (1999) p53 in embryonic development: maintaining a fine balance. Cell Mol Life Sci 55: 38-47.
19. Mario ́n RM, Strati K, Li H, Murga M, Blanco R, et al.(2009) Ap53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460: 1149-1153.
20. Hong H, Takahashi K, Ichisaka T, Aoi T, Kanagawa O, et al. (2009) Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460: 1132-1135.
21. Olovnikov IA, Kravchenko JE, Chumakov PM (2009) Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defence. Semin Cancer Biol 19: 32-41.
22. Lynch CJ, Milner J (2006) Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency. Oncogene 25: 3463-3470.
23. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Jr., et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
24. Tyner SD, Venkatachalam S, Choi J, Jones S, Ghebranious N, et al. (2002) p53 mutant mice that display early ageing-associated phenotypes. Nature 415: 45-53.
25. Maier B, Gluba W, Bernier B, Turner T, Mohammad K, et al. (2004) Modulation of mammalian life span by the short isoform of p53. Genes Dev 18: 306-319.
26. Campisi J (2008) Aging and cancer cell biology. Aging Cell 7: 281-284.
27. García-Cao I, García-Cao M, Martín-Caballero J, Criado LM, Klatt P, et al. (2002) ''Super p53'' mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 21: 6225-6235.
28. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, et al. (2007) Delayed ageing through damage protection by the Arf/p53 pathway. Nature 448: 375-379.
29. Matheu A, Maraver A, Serrano M (2008) The Arf/p53 pathway in cancer and aging. Cancer Res 68: 6031-6034.
30. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W (2008) Acetylation is indispensable for p53 activation. Cell 133: 612-626.
31. Luo J, Nikolaev AY, Imai S, Chen D, Su F, et al. (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 107: 137-148.
32. Vaziri H, Dessain K, Ng Eaton E, Imai SI, Frye RA, et al. (2001) hSIR2 (SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107: 149-159.
33. Finkel T, Serrano M, Blasco MA (2007) The common biology of cancer and ageing. Nature 448: 767-774.
34. Xiao R, Sun Y, Ding JH, Lin S, Rose DW, et al. (2007) Splicing regulator SC35 is essential for genomic stability and cell proliferation during mammalian organogenesis. Mol Cell Biol 27: 5393-5402.
35. Long JC, Caceres JF (2009) The SR protein family of splicing factors: master regulators of gene expression. Biochem J 417: 15-27.
36. Beausoleil SA, Jedrychowski M, Schwartz D, Elias JE, Ville ́n J, et al. (2004) Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci 101: 12130-12135.
37. Ford J, Ahmed S, Allison S, Jiang M, Milner J (2008) JNK2-dependent regulation of SIRT1 protein stability. Cell Cycle 7: 3091-3097.
38. Tanno M, Sakamoto J, Miura T, Shimamoto K, Horio Y (2007) Nucleocyto-plasmic shuttling of the NAD+-dependent histone deacetylase SIRT1. J Biol Chem 282: 6823-6832.
39. Maisse C, Guerrieri P, Melino G (2003) p73 and p63 protein stability: the way to regulate function? Biochem Pharmacol 66: 1555-1561.
40. Wei W, Jin J, Schlisio S, Harper JW, Kaelin WG, Jr. (2005) The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. Cancer Cell 8: 25-33.
41. Vaquero A, Scher M, Lee D, Erdjument-Bromage H, Tempst P, et al. (2004) Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol Cell 16: 93-105.
42. Zhao K, Chai X, Clements A, Marmorstein R (2003) Structure and autoregulation of the yeast Hst2 homolog of Sir2. Nat Struct Biol 10: 864-871.
43. Milner J (2009) Cellular regulation of SIRT1. Curr Pharm Des 15: 39-44.
44. Kim EJ, Kho JH, Kang MR, Um SJ (2007) Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol Cell 28: 277-290.
45. Zhao W, Kruse JP, Tang Y, Jung SY, Qin J, et al. (2008) Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451: 587-590.
46. Kim JE, Chen J, Lou Z (2008) DBC1 is a negative regulator of SIRT1. Nature 451: 583-586.
47. Avalos JL, Celic I, Muhammad S, Cosgrove MS, Boeke JD, et al. (2002) Structure of a Sir2 enzyme bound to an acetylated p53 peptide. Mol Cell 10: 523-535.
48. Min J, Landry J, Sternglanz R, Xu RM (2001) Crystal structure of a SIR2 homolog-NAD complex. Cell 105: 269-279.
49. Han K, Yeo G, An P, Burge CB, Grabowski PJ (2005) A combinatorial code for splicing silencing: UAGG and GGGG motifs. PLoS Biol 3: e158.
50. An P, Grabowski PJ (2007) Exon silencing by UAGG motifs in response to neuronal excitation. PLoS Biol 5: e36.
51. Ghidelli S, Donze D, Dhillon N, Kamakaka RT (2001) Sir2p exists in two nucleosome-binding complexes with distinct deacetylase activities. EMBO J 20: 4522-4535.
52. McCord RA, Michishita E, Hong T, Berber E, Boxer LD, et al. (2009) SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging 1: 109-121.
53. Chen D, Bruno J, Easlon E, Lin SJ, Cheng HL, et al. (2008) Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev 22: 1753-1757.
54. Cohen DE, Supinski AM, Bonkowski MS, Donmez G, Guarente LP (2009) Neuronal SIRT1 regulates endocrine and behavioural responses to calorie restriction. Genes Dev 23: 2812-2817.
55. Sasaki T, Maier B, Bartke A, Scrable H (2006) Progressive loss of SIRT1 with cell cycle withdrawal. Aging Cell 5: 413-422.
56. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, et al. (2007) SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 6: 759-767.
57. Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, et al. (2008) SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell 135: 907-918.
58. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, et al. (2009) Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 324: 1289-1293.
59. Cohen HY, Miller C, Bitterman KJ, Wall NR, Hekking B, et al. (2004) Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 305: 390-392.
60. Sasaki T, Maier B, Koclega KD, Chruszcz M, Gluba W, et al. (2008) Phosphorylation regulates SIRT1 function. PLoS One 3: e4020.
61. Kang H, Jung JW, Kim MK, Chung JH (2009) CK2 is the regulator of SIRT1 substrate-binding affinity, deacetylase activity and cellular response to DNA-damage. PLoS One 4: e6611.
62. Chen Y, Sprung R, Tang Y, Ball H, Sangras B, et al. (2007) Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics 6: 812-819.
63. Cheng Z, Tang Y, Chen Y, Kim S, Liu H, et al. (2009) Molecular characterization of propionyllysines in non-histone proteins. Mol Cell Proteomics 8: 45-52.
64. Liu B, Lin Y, Darwanto A, Song X, Xu G, et al. (2009) Identification and characterization of propionylation at histone H3 lysine 23 in mammalian cells. J Biol Chem 284: 32288-32295.
65. Ghosh HS, Spencer JV, Ng B, McBurney MW, Robbins PD (2007) Sirt1 interacts with transducin-like enhancer of split-1 to inhibit nuclear factor kappaB-mediated transcription. Biochem J 408: 105-111.
66. Vaquero A, Scher M, Erdjument-Bromage H, Tempst P, Serrano L, et al. (2007) SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature 450: 440-444.
67. Zhang D, Li S, Cruz P, Kone BC (2009) Sirtuin 1 functionally and physically interacts with disruptor of telomeric silencing-1 to regulate alpha-ENaC transcription in collecting duct. J Biol Chem 284: 20917-20926.
68. Pfister JA, Ma C, Morrison BE, D'Mello SR (2008) Opposing effects of sirtuins on neuronal survival: SIRT1-mediated neuroprotection is independent of its deacetylase activity. PLoS One 3: e4090.
69. Oberosler P, Hloch P, Ramsperger U, Stahl H (1993) p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J 12: 2389-2396.
70. Mosner J, Mummenbrauer T, Bauer C, Sczakiel G, Grosse F, et al. (1995) Negative feedback regulation of wild-type p53 biosynthesis. EMBO J 14: 4442-4449.
71. Miller SJ, Suthiphongchai T, Zambetti GP, Ewen ME (2000) p53 binds selectively to the 5' untranslated region of cdk4, an RNA element necessary and sufficient for transforming growth factor beta- and p53-mediated translational inhibition of cdk4. Mol Cell Biol 20: 8420-8431.
72. Galy B, Cre ́ancier L, Prado-Lourenço L, Prats AC, Prats H (2001) p53 directs conformational change and translation initiation blockade of human fibroblast growth factor 2 mRNA. Oncogene 20: 4613-4620.
73. Riley KJ, Ramirez-Alvarado M, Maher LJ, 3rd (2007) RNA-p53 interactions in vitro. Biochemistry 46: 2480-2487.
74. Li Q, Lee JA, Black DL (2007) Neuronal regulation of alternative pre-mRNA splicing. Nat Rev Neurosci 8: 819-831.
75. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, et al. (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
76. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, et al. (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282: 1497-1501.
77. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM (1996) ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 62: 155-169.
78. Ljungman M, O'Hagan HM, Paulsen MT (2001) Induction of ser15 and lys382 modifications of p53 by blockage of transcription elongation. Oncogene 20: 5964-5971.
79. Rubbi CP, Milner J (2003) p53 is a chromatin accessibility factor for nucleotide excision repair of DNA damage. EMBO J 22: 975-986.
80. Ahmed SU, Milner J (2009) Basal cancer cell survival involves JNK2 suppression of a novel JNK1/c-Jun/Bcl-3 apoptotic network. PLoS One 4: e7305.
81. Ford J, Jiang M, Milner J (2005) Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65: 10457-10463.
82. Warnock LJ, Adamson R, Lynch CJ, Milner J (2008) Crosstalk between site-specific modifications on p53 and histone H3. Oncogene 27: 1639-1644.
83. Gabut M, Mine ́ M, Marsac C, Brivet M, Tazi J, et al. (2005) The SR protein SC35 is responsible for aberrant splicing of the E1alpha pyruvate dehydrogenase mRNA in a case of mental retardation with lactic acidosis. Mol Cell Biol 25: 3286-3294.
84. Jiang M, Milner J (2002) Selective silencing of viral gene expression in HPV positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 21: 6041-6048.